+ cell counts have been extensively studied in antiretroviral-naive HIV-infected patients, data on individuals who have failed combination antiretroviral therapy (cART) are lacking.
), and 26 cells/mm 3 (95% CI, 18-33 cells/mm 3 ), respectively. Differences in the annual CD4 + cell count increase were observed between specific antiretrovirals.
Conclusions. Subjects with у1 virological failure took a longer time to reach a CD4 + cell count 1300 cell/ mm 3 and had a slower annual increase than those without virological failure. Efforts should be made to optimize first-line cART, because this represents the best chance of achieving an effective CD4 + response.
Over the course of a human immunodeficiency virus (HIV) infection, the CD4 + cell count represents the principal surrogate marker for HIV-1 disease progres- + cell count at start of cART, median cells/mm 3 (range) 378 Median VL at start of cART, log 10 copies/mL (range) 4.69 (1.23-7.53 ) Median calendar year of starting cART (range) 2000 (1997-2008) No. of episodes contributed per patient 1 episode 2811 (79) 2 episodes 539 (15) 3 episodes 149 (4) 13 episodes 38 (1) NOTE. Data are no. (%) of patients, unless otherwise indicated. Baseline t0, the baseline for the first contributing episode per patient; cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; VL, viral load.
HIV-infected patients. Considerable interindividual variation has been observed in the reconstitution of CD4 + T lymphocytes, and controversy exists over how best to define immunological success. Some studies have shown that CD4 + cell counts reach a plateau before normalization [4, 5] , whereas other studies have reported a substantial normalization of CD4 + values. For example, among 11800 antiretroviral-naive patients in the EuroSIDA study who achieved an excellent virological response, sustained annual increases in CD4 + cell count were observed for over 15 years, eventually leading to normalization [6] . Most recently, in the study by Kelley et al [7] , a substantial proportion of patients who delayed therapy until their CD4 + cell count decreased to !200 cells/mm 3 did not achieve a normal CD4 + cell count, even after a decade of otherwise effective antiretroviral therapy. These contrasting results may be partly explained by methodological differences between the studies relating to cohort size, statistical analyses, and the threshold values used to define immunological recovery and viral suppression.
The availability of numerous antiretrovirals has provided therapeutic options for patients with virological failure who have been shown capable of viral suppression following use of a different HAART regimen. According to the US Department of Health and Human Services guidelines, the goal of therapy is the same for multiexperienced and antiretroviral-naive patients (ie, to maximally suppress HIV RNA levels) [8] . However, investigation of immunological response is even more of a challenge for HAART-experienced patients than for antiretroviralnaive individuals, because the situation is complicated by the potential emergence of drug resistance mutations, in which viral strains with reduced fitness and pathogenicity may allow the CD4 + cell count to remain at a beneficial level [9, 10] . The kinetics of CD4 + cell counts in individuals who receive multiple HAART regimens after previous virological failure remain unclear. In this study, we report both the rate of CD4 + cell count increase in HAART-experienced HIV-infected patients with у1 virological failures who subsequently achieved viral suppression on initiation of a different HAART regimen and the factors involved.
METHODS

Patients.
We considered all patients in an Italian cohort of HIV-positive subjects who were enrolled when they were antiretroviral naive; this study is known as the ICONA (Italian COhort of Antiretroviral-Naive patients) Foundation Study. For a detailed description of this cohort, see d'Arminio Monforte et al [11] . All patients signed consent forms to participate in the ICONA Foundation Study, in accordance with the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration (1983 revision) . No specific consent for inclusion in the current analysis was needed.
In this cohort, the CD4 + cell count and the HIV RNA viral (30) 371 (27) 150 (30) 104 (33) 1318 (29) Median age, years (range)
36 36 35 35 36 Mode of HIV transmission Intravenous drug use 651 (28) 557 (41) 242 (49) 160 (50) 1610 (36) Homosexual contacts 502 (22) 216 (16) 50 (10) 33 (10) 801 (18) Heterosexual contacts 990 (43) 512 (37) 169 (34) 111 (35) 1782 (40) Other or unknown 174 (8) 83 (6) 34 (7) 14 (4) 305 (7) Median CD4 519 544 580 533 531 Median calendar year of baseline t0 (range) 2001 (1997-2008) 2001 (1997-2008) 2002 (1998-2008) 2004 (1998-2008) 2002 (1997-2008) AIDS diagnosis before starting cART 101 (4) 47 (3) 22 (4) 20 (6) 190 (4) Median nadir CD4 252 257 258 235 254 ( 315 367 372 374 334 Median VL at start of cART, log 10 copies/mL (range) 4.68 (1.23-7.53) 4.76 (1.52-6.71) 4.67 (1.70-6.34) 4.63 (1.70-6.49) 4.7 (1.23-7.53) Median calendar year of starting cART (range) 2001 (1997-2008) 1999 (1997-2008) 1998 (1997-2007) 1998 (1997-2004) 1999 (1997-2008) Nucleoside pair Lamivudine-didanosine 65 (3) 42 (3) 20 (4) 16 (5) 143 (3) Lamivudine-tenofovir 173 (7) 103 (8) 55 (11) 35 (11) 366 (8) Stavudine-lamivudine 155 (7) 139 (10) 55 (11) 24 (8) 373 (8) Stavudine-didanosine 74 (3) 55 (4) 33 (7) 22 (7) 184 (4) Emtricitabine-tenofovir 385 (17) 150 (11) 59 (12) 55 (17) 649 (14) Zidovudine-lamivudine 822 (35) 499 (36) 116 (23) 44 (14) 1481 (33) Zidovudine-didanosine 39 (2) 30 (2) 15 (3) 6 (2) 90 (2) Other a 604 (26) 350 (26) 142 (29) 116 (36) 1212 (27) Third drug Abacavir 326 (14) 159 (12) 74 (15) 47 (15) 606 (13) Efavirenz 471 (20) 227 (17) 70 (14) 28 (9) 796 (18) Indinavir 145 (6) 127 (9) 19 (4) 1 (0.3)
292 (6) Indinavir-ritonavir boosted
16 (1) 16 (1) 4 (1) 5 (2) 41 (1) Lopinavir-ritonavir boosted 207 (9) 98 (7) 74 (15) 57 (18) 436 (10) Nelfinavir 97 (4) 76 (6) 32 (6) 10 (3) 215 (5) Nevirapine 320 (14) 209 (15) 49 (10) 19 (6) 597 (13) Saquinavir-ritonavir boosted
8 (1) 3 (1) 2 (1) 22 (0.5)
Atazanavir-ritonavir boosted 95 (4) 61 (4) 31 (6) 37 (12) 224 (5) Other a 631 (27) 387 (28) 139 (28) 112 (35) 1269 ( Definitions. Episodes of viral suppression were defined as periods of time in which at least 2 consecutive VLs were р500 copies/mL, with the first of these 2 VL measurements designated as the baseline for the episode in question. The baseline for the first contributing episode per patient was defined as "baseline t0." The time of viral rebound (identifying the end of the episode of VL suppression) was defined as the time of the first of 2 consecutive VL measurements 1500 copies/mL. Virological failure of a single antiretroviral (and therefore the antiretroviral regimen based on this drug) was defined as a VL 1500 copies/mL, despite 14 months of continuous use of the drug in question. Using this definition, we counted every subsequent failure of a regimen containing у1 drug that had not previously failed as an additional regimen failure. Combination antiretroviral therapy (cART) was defined as 2 nucleosides (or nucleotides) plus a single protease inhibitor (PI), a ritonavirboosted PI, a nonnucleoside reverse-transcriptase inhibitor (NNRTI), or abacavir.
Subjects with at least 1 episode of viral suppression after starting first-line cART were included in the study. After a viral rebound, patients who achieved another episode of viral suppression could reenter the analysis, and therefore patients could contribute 11 episode of viral suppression. Statistical analysis. A Kaplan-Meier approach was used to estimate the percentage of patients with an increase in CD4 + cell count 1300 cells/mm 3 . This threshold was chosen because, in the selected population of patients with suppressed VL, most patients experienced high CD4 + cell count increases over time. Alternatively, the time to achieve a CD4 + cell count 1500 cells/ mm 3 in patients with a baseline count !500 cells/mm 3 was investigated. Time to reach this threshold was compared between patients grouped according to the number of previously failed regimens, using a log-rank test.
The rate of CD4 + cell count increase per year was estimated using a multilevel linear model with fixed effects of intercept and slope. Specifically, crude CD4 + cell counts were modeled as a linear function of time from the baseline of each episode of viral suppression р500 copies/mL allowing for a different slope over the intervals 0-1 year, 1-2 years, and у3 years from baseline. Multivariable models were fitted to include the following additional covariates: age, sex, mode of HIV-1 transmission, coinfection with hepatitis C virus, CD4
+ cell count at baseline, VL and CD4 + cell count at first-line cART, CD4 + cell nadir before starting first-line cART, nucleoside pair or third drug used (both fitted as time dependent), and time from firstline cART initiation, with stratification by duration of VL р500 copies/mL. Adjusted estimates of the CD4 + cell count slopes per year were calculated for an arbitrary vector of fixed value for these covariates. The presence of an interaction between the rate of CD4 + cell count increase and the number of regimens that virologically failed prior to baseline was formally tested in the multilevel linear models. In all analyses, the patient's followup was censored at the time of viral rebound, or at the date of last VL measurement for a patient who remained suppressed. All tests were 2-sided, with a level of significance of .05. Analyses were performed using SAS, version 9.1 (SAS Institute). 3 , both at initiation of combination antiretroviral therapy (cART) and baseline, and with a viral load (VL) of 5 log 10 copies/mL at cART, 6 months of suppressed VL to р500 copies/mL, a pre-cART nadir CD4 + cell count of 200 cells/mm 3 , no hepatitis C virus coinfection, and currently receiving combivir and efavirenz. CI, confidence interval.
RESULTS
Patient characteristics.
We studied a total of 3537 patients who contributed 4498 episodes of viral suppression р500 copies/mL: 79% with 1 episode ( ), 15% with 2 episodes n p 2811 ( ), and 5% with 12 episodes ( , of whom 149 n p 539 n p 187 had 3 episodes) ( Table 1) . Not all patients included in our study started their first cART when ART naive; 631 patients (18%) had previously started a mono-dual therapy. The median time from cART initiation to baseline t0 was 6 months (interquartile range [IQR], 1-12 months), and the median duration of viral suppression across all episodes was 29 months (IQR, 13-54 months). A total of 2317 (52%), 1368 (30%), 495 (11%), and 318 (7%) episodes of viral suppression occurred in subjects without previous virological failure or 1, 2, or у3 previous virological failures, respectively ( Table 2 ). The main characteristics of the episodes studied were similar across these groups, although patients with no evidence of previous virological failure were less likely to be intravenous drug users and had delayed start of cART. Furthermore, patients in this group had a lower CD4 + cell count at baseline t0 and a less recent date of baseline t0, compared with patients who had previously experienced multiple virological failure.
Cumulative probability of reaching a CD4 + cell count increase 1300 cells/mm 3 from baseline. The Kaplan-Meier estimate of the median time to reach an increase of 1300 cells/ mm 3 from baseline was 36 months (95% confidence interval [CI], 38-40 months). Figure 1 shows the cumulative probability of reaching this threshold according to the number of previous virological failures. The median time to reach a CD4 + cell count increase of 1300 cells/mm 3 was significantly associated with the number of regimens failed: 34 months (95% CI, 31-37 months), 41 months (95% CI, 36-46 months), 51 months (95% CI, 41-65 months), and 45 months (95% CI, 36-57 months) in subjects without evidence of previous virological failure or 1, 2, or у3 previous virologically failed regimens, respectively ( , by log-rank test). Results were similar when we re-P ! .001 stricted the analysis to patients who had a baseline CD4 + cell count !500 cells/mm 3 and when we compared the time to achieve an absolute count у500 cells/mm 3 according to previous number of failures (data not shown). Figure 2 shows the breakdown of the estimated annual CD4 + cell count increase after stratifying for both these variables at the same time. Association between the number of previously failed regimens and the rate of CD4 + cell count increase (patients with a greater number of previous failures experiencing slower CD4 + cell count increases) was mainly driven by the difference over the first year of viral suppression (Figure 2 ). For example, the annual rate of CD4 + cell count increase for patients with у3 previously failed regimens was significantly slower than it was for patients with no evidence of previous failure overall (12 cells/mm 3 slower per year;
) and especially over the first year of viral sup-P ! .001 pression (37 cells/mm 3 slower per year; ; Table 3 ). P ! .001 Annual rates of CD4 + cell count increase according to the number of previously failed regimens and the current use of specific antiretrovirals. The annual CD4 + cell count slope also varied according to specific antiretrovirals. Table 4 shows the 
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Indinavir 10 (4-16)
12 (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .002 6 (Ϫ7 to 20) .33 19 (Ϫ6 to 44)
. 13 10 (6-14) !.001
Lopinavir-ritonavir booted 1 (Ϫ6 to 7)
.87 9 (0-18) . 05 19 .002 Ϫ12 (Ϫ30 to 6)
. 19 5 (1-9) .03
Saquinavir-ritonavir booted 2 (Ϫ18 to 21)
.87 16 (Ϫ17 to 49) .34 Ϫ7 (Ϫ37 to 24)
.68 53 (Ϫ194 to 299)
.67 2 (Ϫ12 to 17)
.74 Abacavir 3 (Ϫ1 to 6)
.16 Ϫ3 (Ϫ9 to 2)
.24 Ϫ3 (Ϫ12 to 6)
.54 Ϫ20 (Ϫ38 to Ϫ2)
.03 0 (Ϫ3 to 3)
.90
Indinavir-ritonavir booted Ϫ13 (Ϫ28 to 1)
.08 4 (Ϫ11 to 19) .58 17 (Ϫ22 to 56)
.40 Ϫ18 (Ϫ63 to 27)
.44 Ϫ4 (Ϫ14 to 6)
.43
Atazanavir-ritonavir booted Ϫ5 (Ϫ13 to 2)
.18 0 (Ϫ8 to 8)
. 97 18 . , both at initiation of combination antiretroviral therapy (cART) and baseline, and with a viral load (VL) of 5 log 10 copies/mL at cART, 6 months of suppressed VL to р500 copies/mL, a pre-cART nadir CD4 + cell count of 200 cells/mm difference in the annual rate of CD4 + cell count increase according to the specific nucleoside pair (using zidovudine-lamivudine as the comparator) and the third drug administered (using efavirenz as the comparator), both overall and stratified according to the number of previous virologically failed regimens. The rate of CD4 + cell count increase was significantly faster in patients who were currently receiving stavudine-containing pairs, compared with patients who were receiving zidovudine-lamivudine. In contrast, patients receiving a combination, including either emtricitabine-tenofovir or zidovudine-didanosine, experienced a significantly slower CD4 + cell count increase per year. Also, differences were more marked when comparing the effects of specific nucleoside pairs in patients with no previous failures and were less marked in those with previous evidence of virological failure with у1 regimens. The rate of CD4 + cell count increase was faster in patients currently receiving PIs (unboosted indinavir and ritonavir-boosted lopinavir), compared with patients receiving efavirenz, and the rate of CD4 + cell count increase was slower in those receiving nevirapine. In this case, differences were more marked in the group with evidence of previous virological failure with у3 regimens, in which patients on efavirenz had a clinically significantly faster CD4 + cell count increase (20-52 cells/ mm 3 per annum), compared with patients who were currently receiving abacavir, nevirapine, or nelfinavir, respectively.
DISCUSSION
We evaluated the impact of у1 previous virological failures on the annual rate of CD4 + cell count increase in HIV-infected patients with suppressed HIV RNA viremia on cART. Subjects with у1 virological failures took a longer time to reach a CD4 + cell count 1300 cell/mm 3 and had a slower annual CD4 + cell count increase than those with no evidence of virological failure prior to their period of viral suppression.
Other studies have analyzed trends and predictors of CD4 + cell count increase in the context of suppressed viremia, and the literature reporting factors influencing immune reconstitution is extensive [4, 7, 9, [12] [13] [14] [15] . However, the current investigation differs from other published studies, because the analysis focused on the impact of previous virological failures on the probability of achieving a CD4 + cell count recovery. A similar study based on the Swiss HIV cohort analyzed multiple switches of HAART, which was shown not to affect the recovery of CD4 + cell count, but in this case the frequent modification of antiretroviral therapies was mainly due to intolerance or inconvenience [16] .
An important observation from our data is that a greater number of previous virological failures was associated with a slower annual CD4 + cell count increase. Even after viral suppression р500 copies/mL for as long as 2 years, patients with a history of extensive virological failure (у3 regimens) maintained a slower rate of CD4 + cell count increase, compared with those who had never previously experienced failure. This association was stronger over the first year of viral suppression when the difference in annual slope between patients with a past history of failure with at least 2 regimens and those with no previous failure was the greatest. It is known that a rapid increase in CD4 + cell count occurs during the first months following initiation of cART in cART-naive patients, followed by a second phase involving a slower rise [9, 17, 18] . Our data suggest that previous virological failure may impair this early CD4 + cell count response to future suppressive regimens. Therefore, although a resuppression of HIV RNA after previous failure is achievable, this virological success may not reset the clock in terms of achieving the same CD4 + cell count response typically observed in patients who start cART for the first time.
The mechanism underlying poor immune recovery in subjects with resuppressed viremia after previous virological failure is not clear. However, other published studies have suggested that the inability to suppress VL to undetectable levels does not necessarily imply that antiretroviral treatment is no longer having a beneficial effect in terms of CD4 + cell count, especially if cART is keeping the VL below pre-cART levels [19] . Deeks et al [10] demonstrated that CD4 + cell counts remained stable even when plasma HIV RNA rebounded on antiretroviral therapy, suggesting reduced pathogenicity of the virus. Previous studies showing that CD4 + immune recovery is significantly associated with a more sustained reduction in plasma HIV-1 RNA levels are also of relevance. For example, in a study by Kaufmann et al [17] , individuals with 125% detectable HIV-1 RNA levels showed a trend toward a poorer recovery of CD4 + T lymphocytes, compared with those successfully treated with cART.
In the present study, differences were observed between specific antiretrovirals. First, a trend for a slower CD4 + cell count increase was noted in subjects who were currently receiving emtricitabinetenofovir or zidovudine-didanosine, compared with patients receiving a stavudine-containing nucleoside pair, with the caveat that these regimens were compared with zidovudine-lamivudine in the analysis. This result is consistent with findings of previous observational studies [13, 15] . Second, in relation to the third drug, and in comparison with efavirenz, the rate of CD4 + cell count increase was faster in patients currently receiving PIs (unboosted indinavir and lopinavir-ritonavir) and slower in those receiving nevirapine. In other studies, the comparison of CD4 + cell count recovery, according to NNRTI-and PI-based regimens, has led to contradictory results. In the study by Wolbers et al [15] , the authors observed a trend for higher CD4 + cell count increases in the first 5 years of suppression after treatment with boosted PI regimens, compared with NNRTI-based regimens. More recently, no difference was observed when comparing the CD4 + cell count increase over time in patients receiving nonboosted PI-, NNRTI-, or boosted PI-based regimens [20] . Direct comparison of results from analyses evaluating immune recovery by drug class is extremely difficult because of differences in the definitions of outcome and virus exposure employed. In addition, one bias is that NNRTIs are often prescribed to potentially nonadherent patients as a result of once daily dosing. Therefore, it is not possible to know from this analysis how much of a difference in CD4 count slope is truly a drug class effect or a behavioral effect that cannot be adequately controlled for (eg, nonadherence).
In this and other observational studies, drug usage was analyzed using time-dependent covariates, so the differences observed may be due to channelling bias: less potent but also less toxic drugs were started and/or used in patients with an acceptable CD4 + cell count profile, while more potent drugs were used in individuals exhibiting a low CD4 + cell count. Lack of randomization and possible bias due to confounding represent the main limitations of this study, and indeed observational studies in general, especially for the comparison between specific antiretrovirals. Another possible limitation is the absence of data on the association between prevalence of drug resistance and virological failure. The comparison of annual CD4 + cell count slopes between groups could also be confounded by different unmeasured mutation patterns, although analysis of the data from large observational studies showed little evidence for an association between specific mutations and CD4 + count slope [21] . Furthermore, it must be noted that the absolute difference in yearly slope between the groups studied was small for most comparisons and unlikely to reflect real clinical differences, at least in the short term. The main strengths of the study are the large numbers of participants, the long-term follow-up, and the fact that the patients were the real-world patients of clinical practice.
In conclusion, a history of virological failure is likely to have an impact on a patient's immune recovery following initiation of a new suppressive regimen. Every effort should be made to optimize first-line antiretroviral therapy in order to guarantee continuous suppression of HIV RNA, because this represents the best chance of achieving an effective CD4 + cell response.
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